European Journal of Clinical Pharmacology

, Volume 60, Issue 4, pp 265–268

Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays


    • GlaxoSmithKline Research & DevelopmentClinical Pharmacology & Discovery Medicine
  • R. L. Kunka
    • GlaxoSmithKline Research & Development
  • Y. Yin
    • GlaxoSmithKline Research & Development
  • S. M. Andrews
    • GlaxoSmithKline Research & Development
  • S. Callejas
    • GlaxoSmithKline Research & Development
  • C. Ng
    • GlaxoSmithKline Research & Development
Pharmacokinetics and Disposition

DOI: 10.1007/s00228-004-0763-y

Cite this article as:
Daley-Yates, P.T., Kunka, R.L., Yin, Y. et al. Eur J Clin Pharmacol (2004) 60: 265. doi:10.1007/s00228-004-0763-y



To compare the systemic exposure for intranasal mometasone furoate (MF) and fluticasone propionate (FP) aqueous nasal sprays (ANS) in terms of serum and urinary cortisol parameters and plasma pharmacokinetics.


Twelve healthy subjects completed this three-way, cross-over study. They received FPANS (50 μg/spray), MFANS (50 μg/spray) or placebo ANS, eight sprays per nostril every 8 h for 4 days. Cortisol measurements were made at baseline and day 4. FP and MF plasma concentrations were also measured on day 4.


MFANS produced similar mean plasma AUC (123 pmol/l h) to FPANS (112 pmol/l h). Despite the use of high doses, necessary to generate adequate pharmacokinetic data, only minor reductions in cortisol parameters were found, with no difference between FPANS and MFANS.


FP and MF have similar and very low systemic bioavailability when administered intranasally using a high-dose regimen. It is therefore unlikely that therapeutic doses of intranasal FP or MF will produce dissimilar or significant degrees of systemic exposure or systemic effects.


Fluticasone propionateMometasone furoateNasal bioavailability

Copyright information

© Springer-Verlag 2004